DOCSLIB.ORG

Original Articles

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Original Articles 108 THE NATIONAL MEDICAL JOURNAL OF INDIA VOL. 5, NO.3 Iopanoic acid as an adjunct to carbimazole in the management of hyperthyroidism S. K. GUPTA, A. MITHAL, M. M. GODBOLE ABSTRACT (rT3) concentrations in normal subjects' and patients Background. The thiourea drugs take a few weeks to with hyperthyroidism- by inhibiting extra thyroidal control the symptoms of hyperthyroidism whilst iodine iodothyronine 5'-deiodinase activity." It may also inhibit containing radiographic contrast agents (iopanoic acid the release of thyroid hormone from the thyroid gland by and sodium ipodate) have a more rapid effect. There is no virtue of its iodine content. Iopanoic acid and sodium report on the use of iopanoic acid administered in con- ipodate have been used as sole agents=' or as adjuncts junction with carbimazole, so we evaluated the efficacy to propylthiouracil' or methimazole" in the management of this combination in the early medical management of of hyperthyroidism. patients with hyperthyroidism. The thiourea drugs such as carbimazole inhibit thyroid Methods. Thirty hyperthyroid patients diagnosed by hormone synthesis and clinical benefit may take a few clinical and biochemical criteria were randomized into two weeks to manifest. As IA acts more quickly it may provide treatment groups. Group A (n= 16) received iopanoic rapid clinical relief to patients with hyperthyroidism. acid (500 mg orally twice a day for the first 3 weeks) and We therefore conducted a prospective, randomized, carbimazole (30 mg orally in three divided doses) while controlled trial to assess the efficacy of a combination of group B (n=14) received carbimazole alone. Clinical exami- nation and estimation of serum total T3, total T4 and TSH IA with carbimazole in the treatment of such patients. were done by radioimmunoassay at the start of therapy, weekly for 4 weeks and then at 6, 8 and 12weeks. PATIENTS AND METHODS Results. In the initial 3 weeks, iopanoic acid induced a Thirty patients with hyperthyroidism diagnosed by significantly greater fall in mean serum total T3 levels clinical and biochemical criteria were included in the (Z=2.298, p<0.02) and a slower fall in mean serum total T4 study. Informed consent was obtained from all the (Z=2.396, p<0.05) in group A patients compared to those in group B. This was accompanied by earlier clinical improve- patients. They were randomized into two treatment ment in group A patients. The mean serum total T3 and groups. T4 values rose to higher levels in group A at 4 weeks, one Group A: 16 patients who received 30 mg per day of week after discontinuation of iopanoic acid. At the end of carbimazole (Neo-Mercazole=, Nicholas Laboratories, 12 weeks, however, there was no significant difference in India) orally in three divided doses along with iopanoic the mean serum total T3 and T4 levels between the two acid (Telepaque'", Dey's Medical Stores, India) in a groups (p>0.05). Biochemical euthyroidism (i.e. total T3<3 dose of 500 mg orally twice a day. While IA was stopped nmol/L and total T4<170 nmollL) was achieved later in after 3 weeks, carbimazole was continued. group A patients than in group B (10.4±5.0weeks v. 3.6±1.2 Group B: 14 patients who received carbimazole alone in weeks, p<O.OOOl). an oral dose of 30 mg per day. Conclusions. Iopanoic acid given together with carbimazole induces rapid clinical improvement in hyperthyroid patients Clinical examination and biochemical investigations than carbimazole alone. However, the delayed achievement were carried out before starting therapy, then at weekly of euthyroidism may preclude its routine use in the manage- intervals for 4 weeks and at 6, 8 and 12 weeks after treat- ment of patients with hyperthyroidism except in those with ment. A detailed proforma was used for assessing the thyrotoxic emergencies. symptoms and signs. A blood sample was drawn, the serum separated and stored at - 20°C till the time of INTRODUCTION assay. The radiographic contrast agent, iopanoic acid (IA) has The estimations of serum total T4 (TT4) , total T3 (TT3) been reported to reduce the serum levels of triiodo- and TSH were done by radioimmunoassay (RIA) method thyronine (T3) and increase reverse triiodothyronine using commercially available kits. The sensitivities of the TT3, TT4 and TSH assays were 0.18 nmollL, 32 nmollL and 1 mUlL. The inter-assay and intra-assay variations of Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226001, Uttar Pradesh, India TTI, TT4 and TSH in our laboratory are 1.03-3.00 nmollL, S. K. GUPTA, A. MITHAL, M. M. GODBOLE 7(}-170 nmollL and less than 5 mUlL respectively. We Department of Medical Endocrinology could not use a more sensitive TSH assay as it was not Correspondence to A. MITHAL available to us when the study was started. © The National Medical Journal of India 1992 GUPTA er al. : IOPANOIC ACID IN HYPERTHYROIDISM 109 The dose of carbimazole was reduced once the patients Biochemical euthyroidism (i.e. normal TT4 and TT3) became clinically and biochemically euthyroid. was achieved in a mean period of 10.4± 5.0 weeks (range: 6-20 weeks). Four patients continued to be hyperthyroid Statistical analysis at 12weeks and became euthyroid by 17±2 weeks (range: The basal TT4 and TT3 values were compared using 16-20 weeks). The baseline serum TT3 and TT41eveis of Student's t-test while the subsequent values were analysed these slow responders were not significantly different by the Z-test.7 A Z-value of 1.96 or more was considered from the rest of the group. significant. The .serum thyroid hormone concentrations Clinical improvement was observed in 14 patients at were expressed as percentages of their basal values. 1 week and in all 16 patients by 2 weeks. There was a steady weight gain and a progressive decline in resting RESULTS pulse rate till 3 weeks. Thereafter, 11 patients had an The two groups of patients were similar in age and sex increase in pulse rate (12±4 beats/minute) after 4 and distribution and baseline hormone levels. 6 weeks (Table I) and 4 lost weight (mean 1.5 kg; Table II). Two patients developed tremors and one had lid lag. Group A No side-effects were observed during or after IA The mean age (±SD) of the patients in this group was administration. 35.5±1O.6 years (range: 13-50 years) and 10patients were females (57%). The mean basal serum TT4 and TT3 Group B levels were 322±117 nmol/L (range: 200-514) and The mean age and sex distribution of patients in this group 6.3±1.9 nmollL (range: 3.1-11.3) respectively. The mean was not significantly different from those in group A (age: serum TT3 levels showed a rapid decline over the first 40± 10.8 years, range 20-60 years; females: 8,57%). The 3 weeks to 38% of the baseline. Thereafter, it increased mean serum TT4 and TT3 levels were 255±95 nmollL to higher levels and continued to be high at the end of (range: 180-375) and 7.1±3.9 nmol/L (range: 3.5-13.8) 12 weeks (at 4 weeks: 46%; at 6 weeks: 69%; at 8 weeks: respectively. There was a steady decline in serum TT4 and 80% and at 12weeks: 84% of baseline values, Fig. 1). The TT3 levels over the whole study period (TT4: at 3 weeks mean serum TT4 levels after declining gradually over the 51%, at 4 weeks 47%, at 8 weeks 42%; Figs. 1 and 2). first 3 weeks to 66% of baseline values, rose transiently to Serum TSH levels remained below the level of sensitivity 72% at 4 weeks, before falling again (Fig. 2). Serum TSH of the assay. The mean duration for achieving biochemical levels were below the sensitivity level of our test in all the euthyroidism was significantly shorter (3.75± 1.22 weeks; patients throughout the study. range: 3-6 weeks) in the patients in group B compared to 100 .--------------------------------------------------- 100 --------------------------------------------•.•..• 5~ 1ii ~ 80 -- -------- --- - - - ------- - -------- --.".- _ ••.•• ...,.-=--:.-:. :::.-:':-7--::-::-::-- C Q) IA Discontinued ~ !II o C 80 ---- --------1-------------------------------------- ~~ .~ 5l g E 60: -- .. - E~ 8£ g E 60 --------- ------------ ---.-.------------------ ••••• - o 0 (")<1> U~ ~ g> 40 ------------ ------------.-----------'<t- <1> 40 --.--------.----.----.-.----------- --------- Ejg + ~g> " o I Ejg (ij;::R 20 ---.------------------------------------- ..-------- .... 2 o 20 ---------------------------------------------------- (/) ~ IA Discontinued cJ5~ 0L-~--~2--~3---4~----'6~----~8------1-0----~12 O~~--~_;r__,--~~--~~r_----~----~ 2 4 6 8 10 12 Duration (weeks) Duration (weeks) FIG. 1. Mean serum IT3 percentage changes from baseline in FIG. 2. Mean serum TT4 percentage changes from baseline in groups A and B. Iopanoic acid was discontinued at 3 weeks groups A and B. Iopanoic acid was discontinued at 3 weeks in group A. The dose of carbimazole in group B was in group A. The dose of carbimazole in group B was reduced at 8 weeks reduced at 8 weeks. TABLEI. Serial changes in pulse rate in beats per minute TABLEII. Serial changes in weight in kilograms in groups A andB Period Group A GroupB Period Group A GroupB Basal 116±17 103±9 Basal 4S.6±9.2 47.0±7.6 1 week ·92±12 97±10 ns 1 week 4S.8±9.S 47.1±7.6 2 weeks 46.7±9.7 2 weeks 86±11 93±11 ns 47.6±7.3 3 weeks 47.9±9.4 48.S±7.4 3 weeks 84±8 87±10 ns 4weeks 47.9±9.1* 49.3±7.S 4weeks 9S±12 81±9 6 weeks 48.4±9.3* SO.S±7.8 6weeks 96±12 76±6 t 8 weeks 49.4±9.1 S1.7±7.8 12 weeks Sl.O±9.1* 8weeks 90±16 73±4 t S2.8±S.7 12 weeks 87±13* 71±9 t All values are mean±SD The differences between group A and B are not significant ns not significant * (p<O.Ol) t (p<O.OOl) All values are mean±SD * 4 patients lost weight 110 ,THE NATIONAL MEDICAL JOURNAL OF INDIA VOL.5, NO.3 group A (10.43±4.96, p<O.OO1).
Load more

Recommended publications
  • Wo 2009/081169 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date PCT 2 July 2009 (02.07.2009) WO 2009/081169 A2 (51) International Patent Classification: KJELLSON, Fred [SE/SE]; IoPharma Technologies AB, A61K 49/04 (2006.01) Ideon Science Park, Ole Romers Vag 12, SE-223 70 Lund (SE). KLAVENESS, J o [NO/SE]; IoPharma Technologies (21) International Application Number: AB, Ideon Science Park, Ole Romers Vag 12, SE-223 70 PCT/GB2008/004268 Lund (SE). (22) International Filing Date: (74) Agent: KIDD, Sara; Frank B. Dehn 6 Co., St. Bride's 22 December 2008 (22.12.2008) House, 10 Salisbury Square, London EC4Y 8ID (GB). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, (30) Priority Data: EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, 0725070.7 21 December 2007 (21.12.2007) GB IL, IN, IS, IP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (71) Applicant (for all designated States except US): IO- LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, PHARMA TECHNOLOGIES AB [SE/SE]; Ideon MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, Science Park, Ole Romers Vag 12, SE-223 70 Lund (SE).
    [Show full text]
  • Determination of Thiamazole in Tablet Formulation by Using Reversed Phase Liquid Chromatographic Method
    4th International Symposium on Innovative Approaches in Engineering and Natural Sciences SETSCI Conference November 22-24, 2019, Samsun, Turkey Proceedings https://doi.org/10.36287/setsci.4.6.146 4 (6), 512-515, 2019 2687-5527/ © 2019 The Authors. Published by SETSCI Determination of Thiamazole in Tablet Formulation by Using Reversed Phase Liquid Chromatographic Method Kader Poturcu1+, Ebru Çubuk Demiralay1* 1Arts & Science Faculty, Suleyman Demirel University, Isparta, Turkey *Corresponding author: [email protected] +Speaker: [email protected] Presentation/Paper Type: Oral / Full Paper Abstract – In this study, the amount of thiamazole (methimazole) in pharmaceutical tablet formulation was determined by using reversed phase liquid chromatography method (RPLC). Chromatographic separation was carried out by using YMC Triart C18 (150 mm × 4.6 mm, 3μm, YMC, USA) column. 5% (v/v) acetonitrile-water binary mixture at pH 9.5 was used as a mobile phase. Metronidazole was chosen as an internal standard. Flow rate was 0.8 ml/min and column temperature was 25 °C in chromatographic separation. The studied wavelengths for thiamazole and metronidazole are 260 and 340 nm, respectively. This proposed method was suitably validated with respect to accuracy, precision, linearity, the limit of detection (LOD) and limit of quantification (LOQ). The calibration graph of thiamazole was linear from 4 ppm to 14 ppm. The recovery of the 5 mg thiamazole containing commercial tablet (Thyromazol) was 100.059%. The proposed RPLC method was successfully applied to the determination of thiamazole in commercial tablet formulation. Keywords –Thiamazole, tablet formulation, RPLC method, method validation, recovery. I. INTRODUCTION In the last years thiamazole became also a fashioned model substance for endocrine disruption (thyroid axis) studies thus During the last decades, there has been increasing evidence inhibits the production of the thyroid hormones.
    [Show full text]
  • Thyroid Disease Update
    10/11/2017 Thyroid Disease Update • Donald Eagerton M.D. Disclosures I have served as a clinical investigator and/or speakers bureau member for the following: Abbott, Astra Zenica, BMS, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Novo Nordisk, Pfizer, and Sanofi Aventis Thyroid Disease Update • Hypothyroidism • Hyperthyroidism • Thyroid Nodules • Thyroid Cancer 1 10/11/2017 2 10/11/2017 Case 1 • 50 year old white female is seen for follow up. Notices cold intolerance, dry skin, and some fatigue. Cholesterol is higher than prior visits. • Family history; Mother had history of hypothyroidism. Sister has hypothyroidism. • TSH = 14 (0.30- 3.3) Free T4 = 1.0 (0.95- 1.45) • Weight 70 kg Case 1 • Next step should be • A. Check Free T3 • B. Check AntiMicrosomal Antibodies • C. Start Levothyroxine 112 mcg daily • D. Start Armour Thyroid 30 mg q day • E. Check Thyroid Ultrasound Case 1 Next step should be • A. Check Free T3 • B. Check AntiMicrosomal Antibodies • C. Start Levothyroxine 112 mcg daily • D. Start Armour Thyroid 30 mg q day • E. Check Thyroid Ultrasound 3 10/11/2017 Hypothyroidism • Incidence 0.1- 2.0 % of the population • Subclinical hypothyroidism in 4-10% of the adult population • 5-8 times higher in women An FT4 test can confirm hypothyroidism 13 • In the presence of high TSH and FT4 levels in relation to the thyroid function TSH, low FT4 (free thyroxine) usually signalsTSH primary hypothyroidism12 Overt Mild Mild Overt Euthyroidism FT4 Hypothyroidism Thyrotoxicosis* Thyrotoxicosis vs. hyperthyroidism¹ While these terms are often used interchangeably, thyrotoxicosis (toxic thyroid), describes presence of too much thyroid hormone, whether caused by thyroid overproduction (hyperthyroidism); by leakage of thyroid hormone into the bloodstream (thyroiditis); or by taking too much thyroid hormone medication.
    [Show full text]
  • Pharmacy Reengineering (PRE) V.0.5 Pre-Release Implementation
    PHARMACY REENGINEERING (PRE) Version 0.5 Pre-Release Implementation Guide PSS*1*129 & PSS*1*147 February 2010 Department of Veterans Affairs Office of Enterprise Development Revision History Date Revised Patch Description Pages Number 02/2010 All PSS*1*147 Added Revision History page. Updated patch references to include PSS*1*147. Described files, fields, options and routines added/modified as part of this patch. Added Chapter 5, Additive Frequency for IV Additives, to describe the steps needed to ensure correct data is in the new IV Additive REDACTED 01/2009 All PSS*1*129 Original version REDACTED February 2010 Pharmacy Reengineering (PRE) V. 0.5 Pre-Release i Implementation Guide PSS*1*129 & PSS*1*147 Revision History (This page included for two-sided copying.) ii Pharmacy Reengineering (PRE) V. 0.5 Pre-Release February 2010 Implementation Guide PSS*1*129 & PSS*1*147 Table of Contents Introduction ................................................................................................................................. 1 Purpose ....................................................................................................................................1 Project Description ....................................................................................................................1 Scope ........................................................................................................................................3 Menu Changes ..........................................................................................................................4
    [Show full text]
  • Clinical Thyroidology for Patients Volume 6 Issue 8 2013
    Clinical THYROIDOLOGY th 90 ANNIVERSARY FOR PATIENTS VOLUME 6 ISSUE 8 2013 www.thyroid.org EDITOR’S COMMENTS . .2 Tanda ML et al Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed HYPOTHYROIDISM . 3 Graves’ hyperthyroidism seen at a single center. J Clin Desiccated thyroid extract vs Levothyroxine Endocrinol Metab 2013;98:1443-9. in the treatment of hypothyroidism Levothyroxine is the most common form of thyroid hormone THYROID CANCER . 8 replacement therapy. Prior to the availability of the pure levothy- Stimulated thyroglobulin levels obtained after roxine, desiccated animal thyroid extract was the only treatment thyroidectomy are a good indicator for risk of for hypothyroidism and some individuals still prefer dessicated future recurrence from thyroid cancer. thyroid extract as a more “natural” thyroid hormone. This study Thyroglobulin is a protein secreted only by thyroid cells, both was performed to compare levothyroxine to desiccated thyroid normal and cancerous thyroid cells. After thyroidectomy and extract in terms of thyroid blood tests, changes in weight, psy- removal of most of the normal thyroid cells, blood thyroglobu- chometric test results and patient preference. lin levels are used to detect thyroid cancer recurrence. In this Hoang TD et al Desiccated thyroid extract compared study, the authors examined the ability of thyroglobulin levels with levothyroxine in the treatment of hypothyroidism: measured after initial thyroidectomy to accurately predict the A randomized, double-blind, crossover study. J Clin Endo- chance for future thyroid cancer recurrence in high risk patients. crinol Metab 2013;98:1982-90. Epub March 28, 2013. Piccardo, A.
    [Show full text]
  • MEDICATION GUIDE PROPYLTHIOURACIL (Pro-Pil-Thi-O-Ur-A-Sil) Tablets Read This Medication Guide Before You Start Taking Propylthiouracil and Each Time You Get a Refill
    MEDICATION GUIDE PROPYLTHIOURACIL (Pro-pil-thi-o-ur-a-sil) Tablets Read this Medication Guide before you start taking Propylthiouracil and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your doctor about your medical condition or treatment. What is the most important information I should know about Propylthiouracil? Propylthiouracil can cause serious side effects, including: • Severe liver problems. In some cases, liver problems can happen in people who take Propylthiouracil including: liver failure, the need for liver transplant, or death. Stop taking Propylthiouracil and call your doctor right away if you have any of these symptoms: • fever • loss of appetite •nausea • vomiting • tiredness • itchiness • pain or tenderness in your right upper stomach area (abdomen) • dark (tea colored) urine • pale or light colored bowel movements (stools) • yellowing of your skin or whites of your eyes • Serious risks during pregnancy. Propylthiouracil may cause liver problems, liver failure and death in pregnant women and may harm your unborn baby. Propylthiouracil may also cause liver problems or death of infants born to women who take Propylthiouracil during certain trimesters of pregnancy. Propylthiouracil may be used when an antithyroid drug is needed during or just before the first trimester of pregnancy. If you get pregnant while taking Propylthiouracil, call your doctor right away about your therapy. What is Propylthiouracil? Propylthiouracil is a prescription medicine used to treat people who have Graves’ disease with hyperthyroidism or toxic multinodular goiter. Propylthiouracil is used when: • certain other antithyroid medicines do not work well. • thyroid surgery or radioactive iodine therapy is not a treatment option.
    [Show full text]
  • Gold Dissolution in Acid Thiourea-Thiocyanate Solutions Using Ferric As Oxidant
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by The University of Utah: J. Willard Marriott Digital Library University of Utah Institutional Repository Author Manuscript Thiourea-thiocyanate leaching system for gold a b b b a Xiyun Yang , Michael S. Moats , Jan D. Miller , Xuming Wang , Xichang Shi , a Hui Xu a UU IR Author Manuscript School of Metallurgical Science and Engineering, Central South University, Hunan 410083, China bDepartment of Metallurgical Engineering, College of Mines and Earth Sciences, University of Utah, Salt Lake City, Utah 84112, USA Abstract: The leaching of gold in thiourea-thiocyanate solutions has been studied by the rotating-disk technique using ferric sulfate as oxidant. The effects of initial concentrations of ferric, thiourea (Tu) and thiocyanate as well as temperature and pH values on gold leaching rates were studied. An initial gold leaching rate in the order of -9 -2 -1 10 mol cm s was obtained at 25℃, which was higher than rates obtained when either ferric-thiocyanate or ferric-thiourea solutions were used separately. The synergistic effect was attributed to the formation of a mixed ligand complex UU IR Au(Tu)2SCN. Determinations of apparent activation energy indicate that the process was controlled by a combination of chemical reaction and diffusion in the mixed lixiviant system. Open circuit potentials show that thiocyanate stability is increased in Author Manuscript the mixture. Keywords: Gold dissolution; Thiourea; Thiocyanate; Synergistic effect 1. Introduction Corresponding author:Tel.:+86 731 88877352; fax:+86 731 88710171 E-mail address:[email protected](Xiyun Yang) University of Utah Institutional Repository Author Manuscript A possible alternative reagent to cyanide for gold leaching is thiocyanate, as first reported by White (1905).
    [Show full text]
  • Radionuclide Thyroid Scans
    Radionuclide Thyroid Scans Report 2003 1 Purpose The purpose of this guideline is to assist specialists in Nuclear Medicine and Radionuclide Radiology in recommending, performing, interpreting and reporting radionuclide thyroid scans. This guideline will assist individual departments in the formulation of their own local protocols. Background Thyroid scintigraphy is an effective imaging method for assessing the functionality of thyroid lesions including the uptake function of part or all of the thyroid gland. 99TCm pertechnetate is trapped by thyroid follicular cells. 123I-Iodide is both trapped and organified by thyroid follicular cells. Common Indications 1.1 Assessment of functionality of thyroid nodules. 1.2 Assessment of goitre including hyperthyroid goitre. 1.3 Assessment of uptake function prior to radio-iodine treatment 1.4 Assessment of ectopic thyroid tissue. 1.5 Assessment of suspected thyroiditis 1.6 Assessment of neonatal hypothyroidism Procedure 1 Patient preparation 1.1 Information on patient medication should be obtained prior to undertaking study. Patients on Thyroxine (Levothyroxine Sodium) should stop treatment for four weeks prior to imaging, patients on Tri-iodothyronine (T3) should stop treatment for two weeks if adequate images are to be obtained. 1.2 All relevant clinical history should be obtained on attendance, including thyroid medication, investigations with contrast media, other relevant medication including Amiodarone, Lithium, kelp, previous surgery and diet. 1.3 All other relevant investigations should be available including results of thyroid function tests and ultrasound examinations. 1.4 Studies should be scheduled to avoid iodine-containing contrast media prior to thyroid imaging. 2 1.5 Carbimazole and Propylthiouracil are not contraindicated in patients undergoing 99Tcm pertechnetate thyroid scans and need not be discontinued prior to imaging.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Thyroid Hormone Regulation of Mrnas Encoding Thyrotropin β-Subunit, Glycoprotein Î
    Thyroid hormone regulation of mRNAs encoding thyrotropin b-subunit, glycoprotein a-subunit, and thyroid hormone receptors a and b in brain, pituitary gland, liver, and gonads of an adult teleost, Pimephales promelas Sean C Lema, Jon T Dickey , Irvin R Schultz and Penny Swanson Abstract Thyroid hormones (THs) regulate growth, morphological transcript levels for TR isoforms a and b (tra and trb) in the development, and migratory behaviors in teleost fish, yet liver and brain, but reduced levels of brain mRNA for the little is known about the transcriptional dynamics of gene immediate-early gene basic transcription factor-binding targets for THs in these taxa. Here, we characterized TH protein (bteb). In the ovary and testis, exogenous T3 elevated regulation of mRNAs encoding thyrotropin subunits and gene transcripts for tshb, glycoprotein hormone a-subunit thyroid hormone receptors (TRs) in an adult teleost fish ( gpha), and trb, while not affecting tra levels. Taken model, the fathead minnow (Pimephales promelas). Breeding together, these results demonstrate negative feedback of T4 pairs of adult minnows were fed diets containing 3,5, on pituitary tshb, identify tra and trb as T3-autoinduced 0 3 -triiodo-L-thyronine (T3) or the goitrogen methimazole genes in the brain and liver, and provide new evidence for 10 days. In males and females, dietary intake of that tshb, gpha, and trb are THs regulated in the gonad of exogenous T3 elevated circulating total T3, while methima­ teleosts. Adult teleost models are increasingly used to zole depressed plasma levels of total thyroxine (T4). In both evaluate the endocrine-disrupting effects of chemical sexes, this methimazole-induced reduction in T4 led to contaminants, and our results provide a systemic assessment elevated mRNA abundance for thyrotropin b-subunit (tshb) of TH-responsive genes during that life stage.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • IRENAT 300 Mg/Ml, Solution Buvable En Gouttes
    1. NAME OF THE MEDICINAL PRODUCT Irenat Drops 300 mg sodium perchlorate, oral drops Sodium perchlorate monohydrate 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml solution (approximately 15 drops) contains 344.2 mg sodium perchlorate monohydrate (equivalent to 300 mg sodium perchlorate) For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Oral drops 4. CLINICAL PARTICULARS 4.1 Therapeutic indications For the treatment of hyperthyroidism, for thyroid blockade in the context of radionuclide studies of other organs using radioactively labelled iodine or of immunoscintigraphy to detect tumours using antibodies labelled with radioiodine. For the detection of a congenital iodine organification defect (perchlorate discharge test). 4.2 Posology and method of administration Posology Adults receive 4-5 x 10 Irenat drops daily (equivalent to 800-1000 mg sodium perchlorate) or, exceptionally, 5 x 15 Irenat drops daily (equivalent to 1500 mg sodium perchlorate) as an initial dose for the first 1-2 weeks. The mean maintenance dose is 4 x 5 Irenat drops (equivalent to 400 mg sodium perchlorate) per day. Children between the ages of 6 and 14 are treated throughout with a dose of 3-6 x 1 or 4-6 x 2 Irenat drops (equivalent to 60-240 mg sodium perchlorate) daily. When used for the perchlorate discharge test following administration of the dose of radioiodine tracer, a single dose is given of 30-50 Irenat drops (equivalent to 600-1000 mg sodium perchlorate) or 300 mg-600 mg/m 2 body surface area in children. As pretreatment for radionuclide studies not involving the thyroid itself and using radioactively labelled drugs or antibodies containing iodine or technetium, Irenat drops should be administered at doses of 10 – 20 drops (equivalent to 200-400 mg sodium perchlorate) and, in isolated cases, up to 50 drops (equivalent to 1000 mg sodium perchlorate) so as to reduce exposure of the thyroid to radiation and to block uptake of radionuclide into certain compartments.
    [Show full text]